Within Biotechnology & Pharmaceuticals industry Black Hawk Acquisition Corporation booked the highest Quick Ratio than Black Hawk Acquisition in the second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the first quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents BKHAU�s has?
What are BKHAU�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BKHAU Quick Ratio	(May 31 2026) Q2	(Feb 28 2026) Q1	(Nov 30 2025) Q4	(Aug 31 2025) Q3	(May 31 2025) Q2
Y / Y Current Liabilities Change	57.34 %	5129.75 %	4557.44 %	5763.7 %	7618.99 %
Y / Y Cash & cash equivalent Change	-	75.72 %	-85.08 %	-95.37 %	-80.11 %
Quick Ratio MRQ	-	0.05	0.01	0.01	0.03
BKHAU's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	4.28 %	10.23 %	11.67 %	22.56 %	3366.35 %
Seq. Cash & cash equivalent Change	-	351.42 %	163.47 %	-79.43 %	-28.18 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Black Hawk Acquisition's Current Liabilities	$ 4 Millions	Visit BKHAU's Balance sheet
Black Hawk Acquisition's Cash & cash equivalent	$ 0 Millions	Visit BKHAU's Balance sheet
Source of BKHAU's Sales		Visit BKHAU's Sales by Geography

Cumulative Black Hawk Acquisition's Quick Ratio

BKHAU's Quick Ratio for the trailling 12 Months

BKHAU Quick Ratio	(May 31 2026) 12 Months	(Feb 28 2026) 12 Months	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months	(May 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	426.01 %	5441.18 %	5628.85 %	6645.61 %	8229.85 %
Y / Y Cash & cash equivalent TTM Growth	-69.48 %	-71.06 %	-76.03 %	-34.21 %	108.12 %
Quick Ratio TTM	0.02	0.02	0.03	0.08	0.29
Total Ranking TTM	# 3812	# 4410	# 3022	# 2250	# 246
Seq. Current Liabilities TTM Growth	11.24 %	40.84 %	58.64 %	111.64 %	1071.79 %
Seq. Cash & cash equivalent TTM Growth	-23.84 %	33.58 %	-49.6 %	-40.47 %	-27.79 %

Quick ratio ranking by company, industry and sector >> Back to BKHAU Financial Strength Comparisons >> Go to Compare BKHAU Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q2 2026 to $3.80 millions, cumulative Quick Ratio remained unchanged at 0.02 below the Black Hawk Acquisition Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Black Hawk Acquisition. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3196.

Explain Quick Ratio?
How much Cash & cash equivalents BKHAU�s has?
What are BKHAU�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 144
Healthcare Sector	# 914
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.75	0.87	0.02
(Feb 28 2025)

Companies with similar Quick Ratio in the quarter ending May 31 2026, within Biotechnology & Pharmaceuticals Industry

Quick Ratio

May 31 2026 MRQ Cash & cash equivalent

May 31 2026 MRQ Current Liabilities

Date modified: 2026-09-19T05:04:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.